Elanco Animal Health Incorporated

NYSE:ELAN

Drug Manufacturers - Specialty & Generic

Healthcare
$26.70 -3.47%

-$0.84 today

Market cap
$13.35B
Beta
1.70
P/E (TTM)
-48.1
EPS (TTM)
-$0.49
52W Low $13.16High $27.72

Volume 5.78M

Average 6.04M

ELAN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Elanco Animal Health IncorporatedNYSE: ELAN

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit grows, but more slowly than its trailing trend

Q3 FY2026 gross profit of $720M rose 18.6% year over year, behind the +29.3% change in trailing-twelve-month gross profit. Sequentially, it fell 9.8% from the prior quarter. Over 3 fiscal years it compounded at +1.3% a year.

Context

  • Gross profit amounted to 43.5% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +18.6% toward the trailing-twelve-month pace of +29.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$720M-9.8% QoQ
Last fiscal yearDec 2025
$2.05B+7.4% YoY
LTMSep 2026
$2.75B+29.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.6%——
1 year+7.4%——
3-year CAGR+1.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
2.05B USD
Year-over-year change
+7.4%
4-year CAGR
-0.3%

Gross Profit vs competitors

How ELAN compares with its peers on the latest reported figures

  • ELAN's LTM Sep 2026 gross profit of $2.75B is the 4th highest of the 6 companies compared; the peer median is $2.92B.
  • Its year-over-year change of +29.3% is the highest of 6, against a peer median of +13.7%.
  • Gross profit amounts to 53.5% of revenue for ELAN, versus a peer median of 62.7%.
ELAN Competitors Peer median
Gross Profit for ELAN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$50.05B +4.1%+3.7%75.4%
ZTSZoetis Inc.LTM Jun 2026$6.75B +2.6%+6.8%70.9%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$2.92B +13.7%+9.9%62.7%
ELANElanco Animal Health IncorporatedLTM Sep 2026$2.75B +29.3%+1.3%53.5%
PAHCPhibro Animal Health CorporationLTM Mar 2026$487.32M +29.2%+11.9%32.5%
NEOGNeogen CorporationLTM Aug 2026$418.98M +14.9%+0.2%47.4%
Peer median (excluding ELAN) $2.92B+13.7%+6.8%62.7%

Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.76B4.41B4.42B4.44B4.72B
Cost of Revenue2.69B2.44B2.48B2.53B2.67B
Gross Profit2.08B1.97B1.94B1.91B2.05B
Gross Margin43.6%44.7%43.9%43.0%43.5%
Research & Development369M321M327M344M368M
Selling, General & Admin1.4B1.27B1.29B1.31B1.43B
Operating Expenses1.77B1.59B1.61B1.66B1.8B
Depreciation & Amortization716M682M694M662M680M
EBITDA409M866M(224M)1.49B676M
EBITDA Margin8.6%19.6%-5.1%33.5%14.3%
Operating Income304M384M326M251M252M
Operating Margin6.4%8.7%7.4%5.7%5.3%
Interest Income000045M
Interest Expense264M256M277M339M220M
Other Income / Expenses(875M)(456M)(1.52B)237M(476M)
Income Before Tax(571M)(72M)(1.2B)488M(224M)
Pre-Tax Margin-12.0%-1.6%-27.1%11.0%-4.8%
Income Tax Expense(88M)6M36M150M8M
Net Income(483M)(78M)(1.23B)338M(232M)
Net Margin-10.1%-1.8%-27.9%7.6%-4.9%
EPS (Basic)(0.97)(0.15)(2.50)0.68(0.47)
EPS (Diluted)(0.97)(0.15)(2.50)0.68(0.47)
Weighted Avg Shares487.2M488.3M492.3M494M496.4M
Weighted Avg Shares (Diluted)487.2M488.3M492.3M497.3M496.4M

Elanco Animal Health Incorporated

NYSE:ELAN

Intrinsic Alpha fair value

Locked

Current Price

$26.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.